Targeting SIRT1 activation can attenuate the effects of hyperglycemia and lead to decreased vascular disruption and neurodegeneration, which may have clinical potential in neurodegenerative diseases that accompany the metabolic disorder. Here, SIRT1 is linked to neurodegenerative disease.